Summary of the Type 1 Diabetes Genetics Consortium Autoantibody Workshop
- PMID: 26405072
- PMCID: PMC4582908
- DOI: 10.2337/dcs15-2008
Summary of the Type 1 Diabetes Genetics Consortium Autoantibody Workshop
Abstract
The Type 1 Diabetes Genetics Consortium (T1DGC) sponsored an Autoantibody Workshop, providing data from a large number of type 1 diabetes-affected sibling pair families with multiple autoantibodies assayed (both islet and nonislet targets) and extensive genetic and clinical information. Multiple groups analyzed the autoantibody data and various forms of genetic data. The groups presented their results at the T1DGC Autoantibody Workshop and compared results across genes and autoantibodies. The reports of the analyses of the autoantibody data with genetic information are contained as individual articles in this supplement. There were several consistent findings that emerged from the T1DGC Autoantibody Workshop. The human MHC (HLA genes) is the major contributor to variation in the presence of islet and nonislet autoantibodies in subjects with established type 1 diabetes. The contribution of non-MHC genes/variants to autoantibody prevalence is dependent on the set of single nucleotide polymorphisms tested, the autoantibody evaluated, and the inclusion criteria for sample selection. On the basis of these results, the HLA alleles DRB1*0101 and DRB1*0404 and the PTPN22 R620W variant are consistently associated with autoimmunity in the T1DGC Autoantibody Workshop data.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
References
-
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167 - PubMed
-
- Rich SS. Mapping genes in diabetes: genetic epidemiological perspective. Diabetes 1990;39:1315–1319 - PubMed
-
- Sosenko JM, Skyler JS, Palmer JP, et al.; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial–Type 1 Study Group . The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013;36:2615–2620 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
